[go: up one dir, main page]

EG24222A - Spiro-azabicyclic compounds useful in therapy - Google Patents

Spiro-azabicyclic compounds useful in therapy

Info

Publication number
EG24222A
EG24222A EG70395A EG70395A EG24222A EG 24222 A EG24222 A EG 24222A EG 70395 A EG70395 A EG 70395A EG 70395 A EG70395 A EG 70395A EG 24222 A EG24222 A EG 24222A
Authority
EG
Egypt
Prior art keywords
spiro
therapy
compounds useful
azabicyclic compounds
azabicyclic
Prior art date
Application number
EG70395A
Other languages
English (en)
Inventor
Balestra Michael
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417084A external-priority patent/GB9417084D0/en
Priority claimed from GBGB9504627.2A external-priority patent/GB9504627D0/en
Application filed by Astra Ab filed Critical Astra Ab
Application granted granted Critical
Publication of EG24222A publication Critical patent/EG24222A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EG70395A 1994-08-24 1995-08-23 Spiro-azabicyclic compounds useful in therapy EG24222A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417084A GB9417084D0 (en) 1994-08-24 1994-08-24 Compounds useful in therapy
GBGB9504627.2A GB9504627D0 (en) 1995-03-08 1995-03-08 Compounds for use in therapy

Publications (1)

Publication Number Publication Date
EG24222A true EG24222A (en) 2008-11-10

Family

ID=26305509

Family Applications (1)

Application Number Title Priority Date Filing Date
EG70395A EG24222A (en) 1994-08-24 1995-08-23 Spiro-azabicyclic compounds useful in therapy

Country Status (33)

Country Link
US (2) US5902814A (xx)
EP (1) EP0777671B1 (xx)
JP (1) JP3708962B2 (xx)
KR (1) KR100366331B1 (xx)
CN (2) CN1056846C (xx)
AR (1) AR031828A2 (xx)
AT (1) ATE192157T1 (xx)
AU (1) AU690735B2 (xx)
BR (1) BR9508751A (xx)
CA (1) CA2196995C (xx)
CZ (1) CZ289512B6 (xx)
DE (1) DE69516524T2 (xx)
DK (1) DK0777671T3 (xx)
EE (1) EE03399B1 (xx)
EG (1) EG24222A (xx)
ES (1) ES2145922T3 (xx)
FI (1) FI112868B (xx)
GR (1) GR3033878T3 (xx)
HU (1) HUT77352A (xx)
IL (1) IL115039A (xx)
IS (1) IS1852B (xx)
MX (1) MX9701292A (xx)
NO (1) NO307707B1 (xx)
NZ (1) NZ292289A (xx)
PL (1) PL183933B1 (xx)
PT (1) PT777671E (xx)
RU (1) RU2148058C1 (xx)
SA (1) SA95160370B1 (xx)
SK (1) SK282366B6 (xx)
TR (1) TR199501053A2 (xx)
TW (1) TW397837B (xx)
UA (1) UA54375C2 (xx)
WO (1) WO1996006098A1 (xx)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
JP4564135B2 (ja) * 1999-07-26 2010-10-20 住友化学株式会社 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶
WO2001066546A1 (en) * 2000-03-09 2001-09-13 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP2004507549A (ja) * 2000-08-28 2004-03-11 コロラド　ステート　ユニバーシティー　リサーチ　ファウンデーション オキサゾリジノン部分を含む化合物およびその使用方法
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20040048795A1 (en) * 2002-02-26 2004-03-11 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US7273872B2 (en) 2002-12-06 2007-09-25 The Feinstein Institute For Medical Research Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
BRPI0412382A (pt) * 2003-07-08 2006-09-19 Astrazeneca Ab composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
AU2005225458B2 (en) 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet
MX2007006743A (es) * 2004-12-15 2007-07-09 Astrazeneca Ab Ligandos del receptor de acetilcolina nicotinica.
ATE489132T1 (de) 2004-12-27 2010-12-15 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch elektrische stimulation des vagus-nervs
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2006071184A1 (en) * 2004-12-28 2006-07-06 Astrazeneca Ab Aryl sulphonamide modulators
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
RU2326787C2 (ru) * 2005-11-09 2008-06-20 Сергей Федорович Бокарев Способ управления крылом, помещенным в текучую среду, при его взаимодействии с этой средой и устройство для его осуществления
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102008015999B4 (de) 2008-03-27 2011-04-21 Novar Gmbh Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage
US9211409B2 (en) * 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US7863291B2 (en) * 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
RS52703B (sr) 2008-06-20 2013-08-30 Astrazeneca Ab Derivat dibenzotiazepina i njegova upotreba
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
MY173229A (en) 2008-11-19 2020-01-07 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
EA029430B1 (ru) 2013-06-21 2018-03-30 Такеда Фармасьютикл Компани Лимитед Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
CN114904142A (zh) 2016-01-20 2022-08-16 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10661112B2 (en) 2016-07-25 2020-05-26 Tonal Systems, Inc. Digital strength training
US11745039B2 (en) 2016-07-25 2023-09-05 Tonal Systems, Inc. Assisted racking of digital resistance
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US10335626B2 (en) 2017-10-02 2019-07-02 Tonal Systems, Inc. Exercise machine with pancake motor
US10589163B2 (en) 2017-10-02 2020-03-17 Tonal Systems, Inc. Exercise machine safety enhancements
US10617903B2 (en) 2017-10-02 2020-04-14 Tonal Systems, Inc. Exercise machine differential
US10486015B2 (en) 2017-10-02 2019-11-26 Tonal Systems, Inc. Exercise machine enhancements
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
JP2023526080A (ja) 2020-05-21 2023-06-20 ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ 迷走神経刺激のためのシステムおよび方法
US11285355B1 (en) 2020-06-08 2022-03-29 Tonal Systems, Inc. Exercise machine enhancements
US11998804B2 (en) 2021-04-27 2024-06-04 Tonal Systems, Inc. Repetition phase detection
US11878204B2 (en) 2021-04-27 2024-01-23 Tonal Systems, Inc. First repetition detection
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH601304A5 (xx) * 1974-02-12 1978-07-14 Buskine Sa
US4028351A (en) * 1971-09-07 1977-06-07 Buskine S.A. Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained
SU495310A1 (ru) * 1974-03-05 1975-12-15 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US5137895A (en) * 1991-04-29 1992-08-11 A. H. Robins Company, Incorporated 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols

Also Published As

Publication number Publication date
AR031828A2 (es) 2003-10-08
ES2145922T3 (es) 2000-07-16
CA2196995A1 (en) 1996-02-29
BR9508751A (pt) 1997-08-12
HK1010370A1 (en) 1999-06-17
IL115039A (en) 2001-08-26
SA95160370B1 (ar) 2006-06-04
SK282366B6 (sk) 2002-01-07
JPH10504561A (ja) 1998-05-06
IS1852B (is) 2003-02-21
NO307707B1 (no) 2000-05-15
DE69516524D1 (de) 2000-05-31
DK0777671T3 (da) 2000-07-24
ATE192157T1 (de) 2000-05-15
FI970762A0 (fi) 1997-02-24
IL115039A0 (en) 1995-12-08
EP0777671B1 (en) 2000-04-26
PL183933B1 (pl) 2002-08-30
RU2148058C1 (ru) 2000-04-27
AU690735B2 (en) 1998-04-30
SK21697A3 (en) 1997-09-10
NO970800D0 (no) 1997-02-21
HUT77352A (hu) 1998-03-30
CN1159808A (zh) 1997-09-17
IS4424A (is) 1997-02-03
EP0777671A1 (en) 1997-06-11
PT777671E (pt) 2000-08-31
FI112868B (fi) 2004-01-30
TW397837B (en) 2000-07-11
CN1099419C (zh) 2003-01-22
KR100366331B1 (ko) 2003-04-10
CZ39297A3 (en) 1997-12-17
AU3401895A (en) 1996-03-14
CZ289512B6 (cs) 2002-02-13
WO1996006098A1 (en) 1996-02-29
FI970762L (fi) 1997-02-24
CA2196995C (en) 2008-05-13
CN1056846C (zh) 2000-09-27
EE03399B1 (et) 2001-04-16
GR3033878T3 (en) 2000-11-30
JP3708962B2 (ja) 2005-10-19
TR199501053A2 (tr) 1996-06-21
CN1284505A (zh) 2001-02-21
US6051581A (en) 2000-04-18
MX9701292A (es) 1997-05-31
DE69516524T2 (de) 2001-01-18
EE9700039A (et) 1997-08-15
NZ292289A (en) 1998-05-27
UA54375C2 (uk) 2003-03-17
US5902814A (en) 1999-05-11
NO970800L (no) 1997-02-21
PL318760A1 (en) 1997-07-07

Similar Documents

Publication Publication Date Title
EG24222A (en) Spiro-azabicyclic compounds useful in therapy
GB9609641D0 (en) Compounds useful in therapy
GB9526546D0 (en) Compounds useful in therapy
GB9421709D0 (en) Therapeutic compounds
GR3033744T3 (en) Therapeutic compounds
ZA9533B (en) Pentolifylline therapy
GB9402641D0 (en) Therapeutic agents
GB9725953D0 (en) Compounds useful in therapy
GB9401879D0 (en) Therapeutic agents
GB9604400D0 (en) Compounds useful in therapy
GB9722287D0 (en) Compounds useful in therapy
GB9403639D0 (en) Therapeutic agents
ZA957122B (en) Spiro-azabicyclic compounds useful in therapy
GB9422497D0 (en) Compounds useful in therapy
GB9411244D0 (en) Compounds useful in therapy
GB9411293D0 (en) Compounds useful in therapy
GB9417501D0 (en) Compounds useful in therapy
GB9402011D0 (en) Therapeutic agents
GB9511585D0 (en) Compounds useful in therapy
GB9511583D0 (en) Compounds useful in therapy
GB9523135D0 (en) Compounds useful in therapy
GB9318116D0 (en) Compounds useful in therapy
GB9322790D0 (en) Compounds useful in therapy
GB9322864D0 (en) Compounds useful in therapy
GB9504627D0 (en) Compounds for use in therapy